For Geron Corporation GERN, 2024 was a transformational year as it saw the FDA approval and commercial launch of Rytelo (imetelstat) for the treatment of low- to intermediate-1 risk myelodysplastic ...

Geron Corporation (NASDAQ:GERN) is one of the 10 Best US Stocks Under $5 to Buy. On May 7, Wedbush reiterated its Outperform rating on Geron Corporation (NASDAQ:GERN) with a price target of $5 on the ...

After decades of work and delay, Geron Corporation is finally approaching its first approval. That should be done by about H1 2024, and although the stock looks properly valued based on revenue ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

A downtrend has been apparent in Geron (GERN) lately with too much selling pressure. The stock has declined 21.2% over the past four weeks. However, given the fact that it is now in oversold territory ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an ...

Shares of Geron (NASDAQ: GERN) finished the week ended June 7 about 32% higher. The market was reacting to news the company's investors had been waiting to hear for decades. On June 6, the U.S. Food ...

Geron (NASDAQ: GERN) stock is getting crushed in Wednesday's trading. The company's share price was down 31.7% as of 3:50 p.m. ET and had been down as much as 38.7% earlier in the session. Geron stock ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Geron's imetelstat has shown promise to treat a rare blood disorder. The drug could have wide oncology applications. Geron had only $173.1 million in cash at the end of 2022. The stock soared nearly ...